Smart Packaging and Connected Devices: Hype, Evidence, and Regulatory Reality

Key Takeaways

• Smart packaging is strongest as infrastructure, not intervention, delivering its most defensible value in measurement accuracy, traceability, and risk detection rather than direct clinical outcome improvement.

• Evidence supports short-term adherence improvement through electronic medication packaging, but durability and translation to clinical outcomes remain inconsistent and under-validated.

• Regulatory expectations scale with claims, not connectivity, meaning systems that interpret data or influence decisions face higher validation and oversight burdens than those that simply record events.

• Supply chain integrity and cold-chain monitoring represent the most mature smart-packaging use cases, supported by regulatory mandates, standardized protocols, and measurable quality outcomes.

• The credibility of smart packaging depends on evidence discipline, requiring sponsors to define the problem first and demand outcome-appropriate validation before positioning packaging as a clinical or behavioral solution.

Smart and connected packaging has moved rapidly from the margins of pharmaceutical operations into mainstream strategic discussions. Once treated as a late-stage design consideration, packaging is now being positioned as an active participant in therapy delivery, clinical development, and supply chain oversight. Sensors, connectivity, and data capture are increasingly presented as tools that can close long-standing gaps between how medicines are designed to be used and how they are actually handled, stored, and taken in the real world.

The promises attached to this shift are expansive. Smart packaging is frequently framed as a way to improve medication adherence, increase visibility across increasingly complex supply chains, engage patients more directly in their care, and generate real-world data that can inform both clinical and commercial decision-making. In an industry under pressure to demonstrate value beyond efficacy alone, these capabilities are understandably appealing.

At the same time, enthusiasm has often outpaced scrutiny. The mere presence of connectivity or sensing capability is frequently treated as a proxy for impact, even when the underlying evidence is uneven or highly context-dependent. This creates a central tension that runs through the smart packaging conversation: technical capability does not automatically translate into validated outcomes. Measurement, monitoring, and data generation are not the same as sustained behavior change, clinical benefit, or regulatory acceptance.

In practice, smart packaging is best understood not as a single technology, but as a category of systems designed to generate objective information about how a medicine is handled or used. Within this category, electronic medication packaging (EMP) represents a well-defined subset in which monitoring functionality is incorporated directly into the medication package itself rather than added as a separate external device.1 EMP systems are distinguished by their proximity to the drug product, allowing them to capture use-related events at the point where patient interaction actually occurs.

Unlike reminder apps or standalone digital health tools, EMP devices integrate sensing and recording capabilities into primary packaging formats such as bottles, caps, or blisters.¹ This integration enables the package to log discrete events — most commonly openings or dose removals — without relying on patient self-reporting. The result is a time-stamped record of access behavior that can be reviewed retrospectively by clinicians, trial teams, or researchers, depending on the context of use.

Smart blister packs provide a concrete illustration of how this approach is implemented. Electronic blister systems have been developed that record the date and time each individual cavity is accessed, creating a granular dosing history tied directly to the packaged product.² These systems are explicitly designed to support adherence monitoring and to assess usability and acceptance as part of their evaluation, particularly in preparation for use in clinical trials or real-world studies.²

A critical clarification is that most smart packaging systems are fundamentally observational rather than interventional. Their primary function is to measure and record behavior, such as when a dose is removed or whether a package has been opened, rather than to directly alter clinical decision-making or enforce adherence. While some systems may incorporate alerts or reminders, their evidentiary foundation rests on improved measurement and visibility, not on demonstrated therapeutic intervention. This distinction becomes essential when assessing claims about outcomes, regulatory classification, and real-world value.

The earliest structured evidence on smart packaging and adherence comes from systematic reviews that focus specifically on electronic medication packaging. This literature evaluates whether packaging-integrated monitoring systems are associated with improved adherence, rather than relying on self-reported behavior or indirect proxies.¹ These reviews establish EMP as a distinct category of adherence-support tools and provide a foundation for assessing their potential value.

At the same time, this early evidence base is marked by important limitations. Studies vary widely in design, endpoints, and duration, and concerns about study quality and reporting bias are explicitly noted.¹ As a result, while associations between EMP use and improved adherence are observed, the strength and generalizability of those findings remain uneven.

One consistent signal across this early literature is that adherence gains are more frequently observed when monitoring systems are integrated into broader care delivery frameworks rather than deployed in isolation.¹ This suggests that smart packaging may function best as part of a coordinated intervention — supporting clinical workflows or patient engagement strategies — rather than as a standalone solution.

More recent evidence has attempted to bring greater rigor to these questions through systematic review and meta-analysis. A comprehensive meta-analysis evaluated electronic adherence monitoring (EAM) interventions across chronic conditions, reviewing 27 studies and including 19 in quantitative synthesis.³ This work provides the most consolidated assessment to date of whether electronically monitored adherence interventions meaningfully change behavior.

Across the included studies, EAM interventions were associated with a statistically significant improvement in medication adherence compared with usual care or control conditions.³ The pooled effect size favored EAM and fell within a moderate range, indicating a measurable, but not transformative, impact on adherence behavior. Importantly, substantial heterogeneity was observed across studies, reflecting differences in patient populations, intervention design, outcome definitions, and study duration.³

While improvements in measured adherence are evident, the evidence becomes far less consistent when extended to downstream clinical outcomes. The same meta-analysis reports limited and inconsistent findings for clinical endpoints, highlighting a gap between improved monitoring or adherence metrics and demonstrable health benefits.³ This distinction is critical, particularly in contexts where smart packaging is positioned as a driver of improved outcomes rather than a measurement tool.

Study duration further constrains interpretation. Most included trials were short-term, limiting conclusions about sustained adherence over time or long-term clinical impact.3 Reflecting these limitations, the authors explicitly call for better-designed, longer-duration studies to clarify whether adherence improvements persist and whether they translate into meaningful clinical benefit.³

Taken together, the evidence supports a nuanced conclusion. Smart packaging–enabled monitoring can improve measured adherence, particularly in the short term and when integrated into care systems. However, the strength of evidence diminishes when moving from adherence metrics to durability and clinical outcomes, underscoring the need for caution in how these technologies are positioned and evaluated.

The role of smart packaging in clinical development is most clearly framed through the lens of data acquisition rather than therapeutic intervention. U.S. Food and Drug Administration (FDA) guidance explicitly recognizes digital health technologies (DHTs) as tools that may be used to collect data remotely from participants in clinical investigations evaluating medical products.⁴ This frames smart packaging not as an experimental add-on but as part of a broader ecosystem of technologies intended to improve the quality, granularity, and timeliness of trial data.

Importantly, the guidance defines DHTs broadly, encompassing both hardware and software components that perform one or more functions related to data collection.⁴ This scope readily accommodates smart packaging systems that record dosing events, capture timestamps, or transmit use-related information. From a regulatory perspective, the relevance of such systems lies less in their novelty and more in how the resulting data are intended to be used within the trial, whether as exploratory signals, secondary endpoints, or inputs into safety or efficacy assessments.

The regulatory weight of this guidance is reinforced by its statutory origin. The FDA issued the DHT recommendations in response to a mandate under the Food and Drug Omnibus Reform Act (FDORA), underscoring that the agency views remote data acquisition as a substantive and durable feature of modern clinical research rather than a temporary accommodation.⁴ This context signals that sponsors should expect sustained regulatory attention to the quality and reliability of digitally collected data.

The practical implication for smart packaging is a shift in emphasis from connectivity to purpose. When used as a data acquisition tool, smart packaging must be validated in proportion to the role its data play in trial decision-making. Systems that generate exploratory or supportive data may face a different evidentiary burden than those used to support primary endpoints or safety determinations. In this sense, the regulatory question is not whether smart packaging can collect data, but whether the data it produces are fit for their intended use and whether the supporting validation matches the claims being made.

The regulatory status of smart packaging hinges less on its physical form than on the role software plays in its intended use. The FDA has adopted the International Medical Device Regulators Forum (IMDRF) definition of Software as a Medical Device (SaMD), describing software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device.5 This definition provides a clear conceptual boundary that is directly relevant to connected packaging systems that incorporate software-driven data processing or interpretation.

To address how such software should be evaluated, the FDA has issued clinical evaluation guidance for SaMD that outlines a converged approach to assessing clinical safety, effectiveness, and performance for software with a medical purpose.5 The guidance focuses on the relationship between intended use, risk, and the level of clinical evidence required, reinforcing that software functionality — rather than novelty or connectivity — drives regulatory expectations.

At the same time, the guidance is explicit about its status. It clarifies that references to “requirements” within the document are intended as considerations and do not themselves constitute binding regulatory mandates.⁵ This distinction is important, as it emphasizes flexibility while still signaling the types of evidence regulators expect when software outputs are positioned to inform medical decisions.

For smart packaging, these frameworks establish a practical boundary. Packaging systems that record or transmit data, such as timestamps of dose removal or environmental conditions, do not automatically fall under SaMD simply by virtue of generating information. Regulatory scrutiny intensifies when software interprets that data, generates recommendations, or directly influences clinical decision-making. In this context, claims are determinative. The more a smart packaging system is positioned as driving medical insight or action, the greater the regulatory burden it assumes, and the more robust its clinical evaluation must be.

Outside of adherence, the strongest and most mature evidence base for smart packaging lies in supply chain integrity. The scale of the problem is well established. Global health authorities estimate that at least one in ten medicines circulating in low- and middle-income countries are substandard or falsified, creating significant risks for patients and healthcare systems alike.⁶ The economic impact of these products is substantial, with annual losses estimated in the tens of billions of dollars.⁶ These figures provide a clear rationale for packaging-centered interventions that focus on authentication, traceability, and tamper evidence.

Regulatory frameworks in major markets have translated this risk into concrete packaging requirements. In the European Union, medicinal products must carry obligatory safety features on their outer packaging, specifically a unique identifier to enable verification of authenticity and an anti-tampering device to indicate whether the package has been opened or altered.⁷ These requirements embed packaging directly into the regulatory strategy for combating falsified medicines and position smart or connected features as enablers of compliance rather than optional enhancements.

In the United States, similar objectives are articulated through the Drug Supply Chain Security Act (DSCSA). FDA guidance describes a system intended to achieve interoperable, electronic, package-level identification and tracing of certain prescription drugs as they move through the supply chain.8 The statute and its implementing guidance emphasize prevention of illegitimate products from entering the supply chain, rapid detection if they do, and efficient response mechanisms to protect patients.⁸ Verification system requirements further formalize expectations around investigation, quarantine, and disposition of suspect or illegitimate products, reinforcing the role of packaging as a foundational element of supply chain oversight.⁹

In this context, smart packaging functions less as a behavioral tool and more as infrastructure. Its value is tied to system-wide visibility, authentication, and regulatory compliance, areas where outcomes are defined in terms of risk reduction and system integrity rather than individual patient behavior.

Cold chain monitoring represents another domain in which smart packaging has demonstrated clearer and more consistent value. Studies conducted using standardized World Health Organization protocols have documented temperature excursions in vaccine cold chains, highlighting vulnerabilities during storage and transport that can compromise product quality and effectiveness.¹⁰ These findings underscore the limits of relying solely on process controls or environmental assumptions in complex distribution networks.

Smart packaging technologies, particularly time–temperature indicators, address this gap by providing product-level evidence of exposure conditions. Experimental studies have demonstrated indicators capable of detecting relatively small temperature changes within narrow subzero ranges, supporting applications where even brief excursions can have significant consequences for product stability.¹¹ Unlike adherence-focused systems, these technologies are directly aligned with well-defined quality attributes and established stability requirements.

Taken together, anti-counterfeiting, traceability, and cold chain monitoring illustrate where smart packaging delivers its most defensible value today. In these domains, the technologies align with clearly articulated risks, regulatory mandates, and measurable outcomes. As a result, supply chain integrity and temperature monitoring stand out as more mature and evidence-supported applications of smart packaging than efforts to link connectivity directly to improved clinical outcomes.

Viewed across adherence, clinical research, regulatory frameworks, and supply chain applications, a clearer hierarchy of value begins to emerge. The strongest evidence for smart packaging lies in its ability to improve measurement accuracy, increase visibility, and support risk detection and prevention. In these roles, smart packaging functions as reliable infrastructure, capturing objective data about product handling, movement, or use and making that information available to stakeholders who are already equipped to act on it. This is most evident in traceability and cold chain applications, where outcomes are defined in terms of authenticity, integrity, and quality preservation rather than behavior change.

Evidence is more mixed when smart packaging is positioned as a behavioral tool. Short-term improvements in measured adherence are supported by systematic reviews and meta-analyses, particularly when monitoring technologies are integrated into broader care or trial frameworks.^1,3 These findings demonstrate that packaging-enabled monitoring can influence near-term behavior and improve the accuracy of adherence assessment. However, the magnitude of these effects is moderate, and their durability over time remains uncertain.

The weakest evidence appears when claims extend beyond measurement to sustained adherence or direct clinical outcome improvement. Here, study duration is often limited, results are inconsistent, and causal links between packaging-enabled monitoring and health outcomes are difficult to establish.³ This does not negate the potential value of smart packaging, but it does constrain how confidently it can be positioned as a driver of long-term clinical benefit.

Regulatory frameworks reinforce this stratification. Oversight and evidentiary expectations scale with intended use and claims, not with the presence of connectivity alone. Systems that record and transmit data face a different regulatory posture than those that interpret data or influence medical decision-making.^5,12 In practice, this means that smart packaging delivers the clearest value when it is aligned with well-defined risks and use cases (e.g., measurement, visibility, and prevention) rather than when it is asked to carry the burden of outcome improvement without commensurate evidence.

Smart packaging is an increasingly visible element of pharma product development strategy, but it resists simple characterization. It is neither empty hype nor a universal solution. Its impact depends on how clearly it is matched to a defined problem, how carefully outcomes are articulated, and how rigorously evidence is generated to support those claims. Connectivity alone does not confer value; value emerges when data, purpose, and use context are aligned.

Across the applications examined here, a consistent pattern is evident. Smart packaging performs best when treated as infrastructure rather than intervention. In roles that emphasize measurement, visibility, traceability, and risk prevention, it delivers tangible and defensible benefits. In contrast, when smart packaging is positioned as a direct driver of clinical outcomes, the evidentiary bar rises sharply, and current data often fall short of sustaining those claims.

The most credible path forward is therefore grounded in discipline rather than enthusiasm. Sponsors, manufacturers, and technology developers should begin by asking what problem they are trying to solve and whether packaging is the appropriate lever. Where outcome improvement is the goal, claims should be matched to validated evidence and supported by study designs capable of demonstrating durable impact. By putting evidence first and connectivity second, smart packaging can move from a source of inflated expectations to a reliable contributor to pharmaceutical quality, development, and supply chain resilience.

1. Checchi, Kyle D, et al. “Electronic medication packaging devices and medication adherence: A systematic review.” JAMA 312: 1237–1247 (2014).

2. Izzah, Zamrotul, et al. “Electronic Smart Blister Packages to Monitor and Support Medication Adherence: A Usability Study.” Patient Prefer. Adherence. 13: 2543–2558 (2022).

3. Chan, Amy HY, et al. “Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: A systematic review and meta-analysis.” PLOS One. 21 Mar. 2022.

4. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Guidance for Industry, Investigators, and Other Stakeholders. U.S Department of Health and Human Services. Dec. 2023.

5. Software as a Medical Device (SAMD): Clinical Evaluation: Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration. 8 Dec. 2017.

6. “Substandard and falsified medical products.” World Health Organization. 3 Dec. 2024.

7. Directive 2011/62/EU of the European Parliament and of the Council. Official Journal of the European Union. 9 Jun. 2011.

8. “Drug Supply Chain Security.” Title II of the Drug Quality and Security Act. U.S. Food and Drug Administration. 16 Dec. 2014.

9. Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Guidance for Industry. U.S. Food and Drug Administration. Dec. 2023.

10. Falcón, Verónica Carrión, et al. “A vaccine cold chain temperature monitoring study in the United Medican States.” Vaccine. 38: 5202–5211 (2020).

11. Hao, Lam Tan, et al. “Tamper-Proof Time–Temperature Indicator for Inspecting Ultracold Supply Chain.” ACS Omega. 11 Mar. 2021.

12. Digital Health Technologies for Remote Data Acquisition: Guidance for Industry, Investigators, and Other Stakeholders. U.S. Department of Health and Human Services. Dec. 2023.